Some women can continue hormone therapy after age 60 or 65.
The better question is not “What age should women stop?” It’s “Is hormone therapy still appropriate for this woman, with her symptoms, health history, risk factors, labs, and goals?”
For many years, women were often told to stop hormone therapy automatically at age 60 or 65. Current guidance is more individualized. The Menopause Society’s 2022 position statement says hormone therapy does not need to be routinely discontinued in women older than 60 or 65 and may be considered beyond age 65 for persistent vasomotor symptoms, quality-of-life concerns, or osteoporosis prevention after proper evaluation and counseling.
That does not mean hormone therapy is right for everyone forever.
It means age alone should not be the decision-maker.
Why This Question Matters
Many women feel better on hormone therapy.
They sleep better. Hot flashes improve. Night sweats calm down. Vaginal dryness improves. Mood, focus, and quality of life may improve. For some women, hormone therapy also helps protect bone density during a stage of life when fracture risk becomes more important.
The FDA recognizes menopausal hormone therapy for moderate-to-severe hot flashes, vaginal dryness and discomfort, and prevention of bone loss. In February 2026, the FDA approved labeling changes to several menopausal hormone therapy products and removed certain cardiovascular disease, breast cancer, and probable dementia risk statements from the boxed warning, after reviewing updated scientific literature.
But the conversation after age 60 or 65 needs more precision.
A healthy 61-year-old who started hormone therapy around menopause and feels well is not the same as a 67-year-old starting systemic hormones for the first time after a stroke, blood clot, or hormone-sensitive cancer.
Same age group. Very different risk profile.
Starting Hormone Therapy After 60 Is Different Than Continuing It
This is one of the biggest distinctions.
A woman who starts hormone therapy before age 60 or within 10 years of menopause is generally in a more favorable benefit-risk window. The Menopause Society states that benefits outweigh risks for most healthy symptomatic women younger than 60 and within 10 years of menopause onset.
The FDA also notes that randomized studies show women who initiate hormone therapy within 10 years of menopause onset, generally before age 60, have reductions in all-cause mortality and fractures.
Starting systemic hormone therapy later, especially more than 10 years after menopause or after age 60, may carry a less favorable risk-benefit ratio because absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia rise with age.
That does not mean “never.”
It means the evaluation needs to be much more careful.
Why Some Women Continue Hormone Therapy After 65
Some women continue hormone therapy because symptoms never fully resolved.
Hot flashes and night sweats can last longer than most people expect. The Menopause Society notes that the average duration of hot flashes is 7 to 11 years, and up to 40% of women in their 60s and 10% to 15% of women in their 70s continue to experience hot flashes.
In a retrospective analysis of women older than 65 using hormone therapy, the most common reason for continuing was hot flash control, followed by improved quality of life. The same report noted that many participants used transdermal estrogen, such as patches, gels, or sprays, rather than oral estrogen.
For some women, stopping hormone therapy brings symptoms back.
That matters.
Quality of life is not a vanity metric. Sleep, mood, energy, cognition, intimacy, and daily function affect health in real ways.
The Type of Hormone Therapy Matters
Hormone therapy is not one thing.
The risk profile depends on:
- Estrogen type
- Dose
- Delivery route
- Whether progesterone is needed
- Whether a woman has a uterus
- Personal history of blood clots, stroke, heart disease, breast cancer, uterine cancer, liver disease, or unexplained bleeding
- Age and time since menopause
- Metabolic health, blood pressure, lipids, insulin resistance, weight, smoking status, and family history
Systemic hormone therapy affects the whole body and may be used for symptoms like hot flashes, night sweats, sleep disruption, and bone protection.
Low-dose vaginal estrogen is more localized and is commonly used for genitourinary syndrome of menopause, which includes vaginal dryness, painful intercourse, urinary urgency, and recurrent urinary tract symptoms. The Menopause Society states that vaginal estrogen or other nonestrogen therapies may be used at any age and for extended duration when needed for genitourinary symptoms.
That difference matters.
A woman using low-dose vaginal estrogen for dryness after 65 is not in the same category as a woman starting oral systemic estrogen for whole-body symptoms at 68.
Route Matters: Oral vs Transdermal Estrogen
Oral estrogen and transdermal estrogen do not carry the same risk profile.
The Menopause Society notes that transdermal routes and lower doses may reduce the risk of venous thromboembolism and stroke.
The Society for Endocrinology also states that transdermal estradiol is unlikely to increase venous thrombosis or stroke risk above non-users and is associated with lower risk compared with oral estradiol, especially in women with relevant risk factors.
This is why many clinicians prefer patches, gels, or sprays for certain women, especially as risk factors increase with age.
Again, this is not a blanket rule.
It is a clinical decision.
Women With a Uterus Usually Need Progesterone
If a woman still has her uterus and uses systemic estrogen, she typically needs a progestogen to protect the uterine lining.
Unopposed systemic estrogen can increase the risk of endometrial hyperplasia and endometrial cancer. The Society for Endocrinology notes that women with a uterus require progestogen to minimize this risk.
This is one reason hormone therapy should not be managed casually.
The dose, route, timing, bleeding pattern, and uterine history all matter.
When Continuing Hormone Therapy After 60 or 65 May Make Sense
Continuation may be reasonable when a woman:
- Started hormone therapy closer to menopause
- Still has persistent hot flashes, night sweats, or sleep disruption
- Has significant quality-of-life improvement on therapy
- Has genitourinary symptoms that respond well to local therapy
- Has bone-loss concerns and limited alternatives
- Has no major contraindications
- Uses an appropriate dose and route
- Is monitored regularly
- Understands the potential benefits and risks
The Menopause Society states that longer therapy duration should be used for documented indications, such as persistent vasomotor symptoms, with shared decision-making and periodic reevaluation.
That last part matters: documented indication.
Hormone therapy should have a reason.
When Hormone Therapy May Not Be Appropriate
Systemic hormone therapy may not be appropriate for women with certain risk factors or medical histories.
These may include:
- History of breast cancer or estrogen-sensitive cancer
- Unexplained vaginal bleeding
- History of blood clots
- Prior stroke
- Active liver disease
- High-risk cardiovascular disease
- Uncontrolled severe hypertension
- Certain clotting disorders
The Menopause Society lists breast cancer, uterine cancer, unexplained uterine bleeding, liver disease, history of blood clots, and cardiovascular disease as situations where hormone therapy may not be a good choice.
This does not mean every woman with risk factors has no options.
It means systemic therapy needs careful medical review, and nonhormonal options or localized therapies may be safer.
Hormone Therapy Is Not an Anti-Aging Shortcut
Hormone therapy should not be sold as a magic anti-aging plan.
That is where the conversation often goes off the rails.
The U.S. Preventive Services Task Force recommends against using combined estrogen and progestin, or estrogen alone after hysterectomy, for the primary prevention of chronic conditions in postmenopausal people. Importantly, that recommendation does not apply to women using hormone therapy for menopause symptoms like hot flashes or vaginal dryness.
Translation: hormone therapy may be appropriate for symptoms and selected clinical goals, but it should not be used casually as a blanket prevention strategy for aging.
At 1st Optimal, we look at the full picture: symptoms, labs, sleep, body composition, cardiovascular risk, metabolic health, thyroid function, nutrition, stress, and personal goals.
Because “just take hormones” is not a plan.
What Should Be Checked Before Continuing After 60 or 65?
A smart hormone therapy review should include more than a refill.
A clinician may review:
- Current symptoms and symptom recurrence when stopping
- Personal and family history
- Blood pressure
- Weight, body composition, and waist circumference
- Lipids, including ApoB when appropriate
- Blood sugar markers, including fasting glucose, HbA1c, and fasting insulin when appropriate
- Liver and kidney markers
- Complete blood count
- Thyroid function when symptoms overlap
- Mammogram and breast screening status
- Uterine bleeding history
- Bone density testing when indicated
- Medication list and supplement use
- Smoking status
- Blood clot, stroke, cardiovascular, and cancer history
The goal is not to scare women off therapy.
The goal is to make the decision with better data.
Should Women Taper Off Hormone Therapy?
There is no single perfect stopping strategy.
Some women stop and do fine. Others stop and symptoms return. The Menopause Society notes there is no “right” time to stop hormone therapy, and bothersome hot flashes or night sweats may return after stopping.
Some clinicians taper gradually. Others stop more directly. The best approach depends on the woman, the dose, the symptoms, the formulation, and the reason for stopping.
If symptoms return, the decision should be revisited rather than dismissed.
The 1st Optimal Perspective
Women deserve better than fear-based medicine.
They also deserve better than hormone hype.
The right answer lives in the middle: informed, individualized, medically supervised care.
For some women, continuing hormone therapy after age 60 or 65 may be reasonable. For others, changing the route, lowering the dose, switching to local therapy, or stopping may be safer.
The goal is not to stay on hormones forever.
The goal is to optimize health, function, quality of life, and long-term risk with the best information available.
That starts with listening to the woman in front of us.
Key Takeaways
- Women do not need to stop hormone therapy automatically at age 60 or 65.
- Continuing beyond 65 may be appropriate for persistent symptoms, quality-of-life concerns, or osteoporosis prevention after individualized review.
- Starting systemic hormone therapy after 60 or more than 10 years after menopause requires more caution.
- Route matters. Transdermal estrogen may carry lower clot and stroke risk than oral estrogen for some women.
- Low-dose vaginal estrogen is different from systemic hormone therapy and may be used at any age when appropriate.
- Women with a uterus usually need progesterone with systemic estrogen.
- Hormone therapy should be monitored and personalized.
- It should not be used as a casual anti-aging shortcut.
FAQ
Can a woman stay on hormone therapy after 65?
Yes, some women can. Current guidance does not require automatic discontinuation at 65. Continued use may be considered for persistent symptoms, quality-of-life issues, or osteoporosis prevention after appropriate evaluation and counseling.
Is it safe to start hormone therapy after age 60?
It depends. Starting systemic hormone therapy after age 60 or more than 10 years after menopause may carry higher absolute risks than starting closer to menopause. The decision should be individualized based on symptoms, medical history, and risk factors.
Is vaginal estrogen safe after 65?
Low-dose vaginal estrogen is generally considered different from systemic hormone therapy because very little is absorbed into the bloodstream. The Menopause Society states it may be used at any age and for extended duration when needed for genitourinary symptoms.
Does hormone therapy prevent chronic disease?
Hormone therapy should not be used as a general chronic disease prevention strategy. The U.S. Preventive Services Task Force recommends against systemic hormone therapy for primary prevention of chronic conditions in postmenopausal people, while clarifying that this does not apply to symptom treatment.
What is the best hormone therapy after age 60?
There is no universal “best” option. The safest and most effective plan depends on the woman’s symptoms, uterus status, cardiovascular risk, breast cancer risk, clotting history, bone health, and treatment goals.
Next step:
If you’re wondering whether hormone therapy still makes sense for your body, don’t guess.
At 1st Optimal, we use symptoms, advanced labs, health history, and a personalized medical plan to help women make informed decisions about hormone therapy, weight loss, energy, and long-term health.
Book a call with 1st Optimal to review your options.
